Advisory Committee on the Medical Uses of Isotopes: Call for Nominations, 76113 [2020-26151]

Download as PDF Federal Register / Vol. 85, No. 229 / Friday, November 27, 2020 / Notices NUCLEAR REGULATORY COMMISSION Advisory Committee on the Medical Uses of Isotopes: Call for Nominations U.S. Nuclear Regulatory Commission ACTION: Call for nominations. AGENCY: The U.S. Nuclear Regulatory Commission (NRC) is soliciting for nominations for the Patients’ Rights Advocate representative position on the Advisory Committee of the Medical Uses of Isotopes (ACMUI). Patients’ Rights Advocate nominees should have professional or personal experience with and/or knowledge about patient advocacy. Also, involvement or leadership with patient advocacy organizations is preferred. DATES: Nominations are due on or before January 26, 2021. ADDRESSES: Nomination Process: Submit an electronic copy of resume or curriculum vitae, along with a cover letter, to Ms. Kellee Jamerson, Kellee.Jamerson@nrc.gov. The cover letter should describe the nominee’s current involvement with patients’ rights advocacy and express the nominee’s interest in the position. Please ensure that the resume or curriculum vitae includes the following information, if applicable: Education; certification; professional association membership and committee membership activities; and number of years, timeframe, and type of setting for patient advocacy. FOR FURTHER INFORMATION CONTACT: Ms. Kellee Jamerson, U.S. Nuclear Regulatory Commission, Office of Nuclear Material Safety and Safeguards; (301) 415–7408; Kellee.Jamerson@ nrc.gov. SUMMARY: The ACMUI Patients’ Rights Advocate representative provides advice to the NRC staff on patients’ issues associated with the regulation of medical applications of byproduct material. This advice includes ensuring patients’ rights are represented during the development and implementation of the NRC’s medical-use regulations. This individual is appointed based on his or her professional and personal experience with and/or knowledge about patient advocacy, as well as involvement and/ or leadership with patient advocacy organizations. ACMUI members are selected based on their educational background, certification(s), work experience, involvement and/or leadership in professional society activities, and other jbell on DSKJLSW7X2PROD with NOTICES SUPPLEMENTARY INFORMATION: VerDate Sep<11>2014 19:29 Nov 25, 2020 Jkt 253001 information obtained from recommendation letters or during the selection process. Nominees should have the demonstrated ability to establish effective work relationships with peers and implement successful approaches to problem solving and conflict resolution. ACMUI members currently serve a four-year term and may be considered for reappointment to an additional term. The current ACMUI membership is comprised of the following professionals: (a) Nuclear medicine physician; (b) nuclear cardiologist; (c) nuclear medicine physicist; (d) therapy medical physicist; (e) radiation safety officer; (f) nuclear pharmacist; (g) two radiation oncologists; (h) patients’ rights advocate; (i) Food and Drug Administration representative; (j) Agreement State representative; (k) healthcare administrator; and (l) diagnostic radiologist. For additional information about membership on the ACMUI, visit the ACMUI Membership web page, https://www.nrc.gov/aboutnrc/regulatory/advisory/acmui/ membership.html. Nominees must be U.S. citizens and be able to devote up to 160 hours per year to ACMUI business. Members are expected to attend semi-annual meetings in Rockville, Maryland and to participate in teleconferences, as needed. Members who are not Federal employees are compensated for their service. In addition, members are reimbursed for travel (including per diem in lieu of subsistence) and are reimbursed secretarial and correspondence expenses. Full-time Federal employees are reimbursed for travel expenses only. Security Background Check: The selected nominee will undergo a thorough security background check. Security paperwork may take the nominee several weeks to complete. Nominees will also be required to complete a financial disclosure statement to avoid conflicts of interest. Dated: November 20, 2020. Russell E. Chazell, Advisory Committee Management Officer. [FR Doc. 2020–26151 Filed 11–25–20; 8:45 am] BILLING CODE 7590–01–P PO 00000 Frm 00110 Fmt 4703 Sfmt 4703 76113 NUCLEAR REGULATORY COMMISSION [Docket Nos. 50–003, 50–247, and 50–286; NRC–2020–0251] Holtec Decommissioning International, LLC; Indian Point Nuclear Generating Station, Unit Nos. 1, 2, and 3 AGENCY: Nuclear Regulatory Commission. ACTION: Exemption; issuance. The U.S. Nuclear Regulatory Commission (NRC) is issuing an exemption in response to a February 12, 2020, request from Holtec Decommissioning International, LLC (HDI). The exemption permits HDI to make withdrawals from the Indian Point Nuclear Generating Station, Unit Nos. 1, 2, and 3 (referred to individually as IP1, IP2, and IP3, respectively, and collectively as the Indian Point Energy Center or IPEC) Decommissioning Trust Funds (DTFs) for spent fuel management and site restoration activities for IP1, IP2, and IP3 without prior notification to the NRC. This exemption is effective upon issuance, but only applies to HDI upon the consummation of the transfers of the licenses for IP1, IP2, and IP3 to Holtec International (Holtec) subsidiaries Holtec Indian Point 2, LLC and Holtec Indian Point 3, LLC and the transfer of the operating authority under the licenses to HDI. DATES: The exemption was issued on November 23, 2020. ADDRESSES: Please refer to Docket ID NRC–2020–0251 when contacting the NRC about the availability of information regarding this document. You may obtain publicly available information related to this document by any of the following methods: • Federal Rulemaking website: Go to https://www.regulations.gov and search for Docket ID NRC–2020–0251. Address questions about Docket IDs in Regulations.gov to Jennifer Borges; telephone: 301–287–9127; email: Jennifer.Borges@nrc.gov. For technical questions, contact the individual listed in the FOR FURTHER INFORMATION CONTACT section of this document. • NRC’s Agencywide Documents Access and Management System (ADAMS): You may obtain publicly available documents online in the ADAMS Public Documents collection at https://www.nrc.gov/reading-rm/ adams.html. To begin the search, select ‘‘Begin Web-based ADAMS Search.’’ For problems with ADAMS, please contact the NRC’s Public Document Room (PDR) SUMMARY: E:\FR\FM\27NON1.SGM 27NON1

Agencies

[Federal Register Volume 85, Number 229 (Friday, November 27, 2020)]
[Notices]
[Page 76113]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-26151]



[[Page 76113]]

=======================================================================
-----------------------------------------------------------------------

NUCLEAR REGULATORY COMMISSION


Advisory Committee on the Medical Uses of Isotopes: Call for 
Nominations

AGENCY: U.S. Nuclear Regulatory Commission

ACTION: Call for nominations.

-----------------------------------------------------------------------

SUMMARY: The U.S. Nuclear Regulatory Commission (NRC) is soliciting for 
nominations for the Patients' Rights Advocate representative position 
on the Advisory Committee of the Medical Uses of Isotopes (ACMUI). 
Patients' Rights Advocate nominees should have professional or personal 
experience with and/or knowledge about patient advocacy. Also, 
involvement or leadership with patient advocacy organizations is 
preferred.

DATES: Nominations are due on or before January 26, 2021.

ADDRESSES: Nomination Process: Submit an electronic copy of resume or 
curriculum vitae, along with a cover letter, to Ms. Kellee Jamerson, 
[email protected]. The cover letter should describe the nominee's 
current involvement with patients' rights advocacy and express the 
nominee's interest in the position. Please ensure that the resume or 
curriculum vitae includes the following information, if applicable: 
Education; certification; professional association membership and 
committee membership activities; and number of years, timeframe, and 
type of setting for patient advocacy.

FOR FURTHER INFORMATION CONTACT: Ms. Kellee Jamerson, U.S. Nuclear 
Regulatory Commission, Office of Nuclear Material Safety and 
Safeguards; (301) 415-7408; [email protected].

SUPPLEMENTARY INFORMATION: The ACMUI Patients' Rights Advocate 
representative provides advice to the NRC staff on patients' issues 
associated with the regulation of medical applications of byproduct 
material. This advice includes ensuring patients' rights are 
represented during the development and implementation of the NRC's 
medical-use regulations. This individual is appointed based on his or 
her professional and personal experience with and/or knowledge about 
patient advocacy, as well as involvement and/or leadership with patient 
advocacy organizations.
    ACMUI members are selected based on their educational background, 
certification(s), work experience, involvement and/or leadership in 
professional society activities, and other information obtained from 
recommendation letters or during the selection process. Nominees should 
have the demonstrated ability to establish effective work relationships 
with peers and implement successful approaches to problem solving and 
conflict resolution. ACMUI members currently serve a four-year term and 
may be considered for reappointment to an additional term. The current 
ACMUI membership is comprised of the following professionals: (a) 
Nuclear medicine physician; (b) nuclear cardiologist; (c) nuclear 
medicine physicist; (d) therapy medical physicist; (e) radiation safety 
officer; (f) nuclear pharmacist; (g) two radiation oncologists; (h) 
patients' rights advocate; (i) Food and Drug Administration 
representative; (j) Agreement State representative; (k) healthcare 
administrator; and (l) diagnostic radiologist. For additional 
information about membership on the ACMUI, visit the ACMUI Membership 
web page, https://www.nrc.gov/about-nrc/regulatory/advisory/acmui/membership.html.
    Nominees must be U.S. citizens and be able to devote up to 160 
hours per year to ACMUI business. Members are expected to attend semi-
annual meetings in Rockville, Maryland and to participate in 
teleconferences, as needed. Members who are not Federal employees are 
compensated for their service. In addition, members are reimbursed for 
travel (including per diem in lieu of subsistence) and are reimbursed 
secretarial and correspondence expenses. Full-time Federal employees 
are reimbursed for travel expenses only.
    Security Background Check: The selected nominee will undergo a 
thorough security background check. Security paperwork may take the 
nominee several weeks to complete. Nominees will also be required to 
complete a financial disclosure statement to avoid conflicts of 
interest.

    Dated: November 20, 2020.
Russell E. Chazell,
Advisory Committee Management Officer.
[FR Doc. 2020-26151 Filed 11-25-20; 8:45 am]
BILLING CODE 7590-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.